Psychiatry & Neurology Doctors in Palos Verdes Estates, CA Accepting Medicare

3 Psychiatry & Neurology doctors found. Showing 1 - 3

Dr. Carol Anne Lindberg, MD Psychiatry & Neurology - Psychiatry Medicare: Accepting Medicare Assignments Practice Location: 344 Tejon Pl, Palos Verdes Estates, CA 90274 Phone: 310-378-0565    Fax: 310-378-0675

Irina Addes, Psychiatry & Neurology - Psychiatry Medicare: Accepting Medicare Assignments Practice Location: 2105 Via Estudillo, Palos Verdes Estates, CA 90274 Phone: 310-922-2126

Douglas Kalunian, M.D. Psychiatry & Neurology - Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 1729 Dalton Rd, Palos Verdes Estates, CA 90274 Phone: 310-749-5150

News Archive

Study examines direct and indirect costs associated with health inequalities for minority men in the U.S.

African-American men incurred $341.8 billion in excess medical costs due to health inequalities between 2006 and 2009, and Hispanic men incurred an additional $115 billion over the four-year period, according to a new study by researchers at the Johns Hopkins Bloomberg School of Public Health. The study, published this week in the International Journal of Men's Health, looks at the direct and indirect costs associated with health inequalities and projects the potential cost savings of eliminating these disparities for minority men in the U.S.

Discovery opens door to more targeted, effective treatments for cancer

In a discovery that could lead to more targeted and effective treatments for certain lung and prostate cancers, researchers at the University of Virginia School of Medicine have identified two new cancer-causing gene mutations - mutations that may be particularly susceptible to cancer-fighting drugs already approved by the federal Food and Drug Administration. One of the gene mutations also may play a key role in early menopause.

Blood pressure reduction supported for early-stage kidney disease

Blood pressure reduction per se, rather than the particular antihypertensive used, reduces the risk for cardiovascular events in patients with chronic kidney disease, shows a meta-analysis published in BMJ.

Positive results from Alnylam's ALN-TTR02 Phase I trial on TTR-mediated amyloidosis

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the achievement of positive clinical results from its Phase I trial with ALN-TTR02, an RNAi therapeutic targeting the transthyretin (TTR) gene for the treatment of TTR-mediated amyloidosis.

New legislation will increase access to health care, says DDI

Will the newly signed health care legislation create a major shift in how pharmaceutical brand decisions are made? The bill will increase access to health insurance, but many believe the practice of medicine is already in transition, and the bill signed by President Obama will simply accelerate changes already being implemented.

Read more Medical News

› Verified 4 days ago